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Which Antidepressant Is Best to Avoid Sexual Dysfunction?  
Searchable Question  
In patients being treated for depression, which antidepressants have a low risk of sexual side 
effects?  
Evidence-Based Answer  
Bupropion (Wellbutrin), nefazodone (Serzone), amitriptyline (Elavil), and moclobemide 
(Manerix, a reversible inhibitor of monoamine oxidase type A not available in the United States) 
have been shown to cause less sexual dysfunction than selective serotonin reuptake inhibitors 
(SSRIs). [Strength of recommendation: B, based on individual randomized controlled trials 
(RCTs)] Among SSRIs, fluvoxamine (Luvox) may cause less sexual dysfunction than sertraline 
(Zoloft). [Strength of recommendation: B, single RCT] No other differences between or within 
classes of antidepressants have been demonstrated in RCTs.  
Evidence Summary  
The incidence of sexual side effects between different antidepressants in adults with depressive 
or anxiety disorders has been reported by 25 RCTs, most of which were included in two recent 
descriptive systematic reviews.
1,2
 [References 1 and 2--Evidence level 1A] Bupropion led to less 
sexual dysfunction (or to more sexual satisfaction) than sertraline or fluoxetine in four trials. The 
number needed to harm (NNH), that is, the number of patients who have to take the drug for one 
patient to experience sexual dysfunction, ranged from two to 17, depending on the type of 
dysfunction.
1,2
 Nefazodone led to less sexual dysfunction (or to more sexual satisfaction) than 
sertraline in two trials (NNH: two to seven).
1-3
 [Reference 3--Evidence level 1B] Moclobemide 
led to less sexual dysfunction than four SSRIs in one trial (NNH: five) and to greater sexual 
desire than doxepin (Adapin) in one trial (number needed to treat: eight).
2-4
 [Reference 4--
Evidence level 1B] The acompanying table
1-4
 summarizes the different adverse sexual effects 
and the agents that cause them.  
 
Significantly Different Adverse Sexual Effects Caused by Various Antidepressants  
 
Outcome  
 
Agents  
 
Increased sexual desire Moclobemide* (Manerix) >doxepin (Adapin) 
Diminished sexual desire Fluoxetine (Prozac) >bupropion (Wellbutrin); sertraline (Zoloft) >nefazodone (Serzone)  
Sexual arousal disorder Sertraline, fluoxetine >bupropion; sertraline >nefazodone 
Ejaculatory abnormality Sertraline >nefazodone 
Orgasm dysfunction, male Sertraline >bupropion  
Orgasm dysfunction, female Sertraline >bupropion 
Orgasm dysfunction, total Sertraline, fluoxetine >bupropion 
Sexual dysfunction, male Sertraline >amitriptyline (Elavil)  
Sexual dysfunction, female Sertraline >nefazodone 
Sexual dysfunction, total Sertraline >fluvoxamine (Luvox), nefazodone; SSRI >moclobemide 
Sexual satisfaction Bupropion, nefazodone >sertraline 
 
> = "is associated with a greater incidence of the measured outcome than"; SSRI = selective 
serotonin reuptake inhibitor.  
*--Not available in the United States.  
note: No significant difference was found for the following: sertraline vs. citalopram 
(Celexa); paroxetine (Paxil) vs. fluvoxamine or fluoxetine; amitriptyline vs. amoxapine 
(Asendin) or mirtazapine (Remeron); clomipramine (Anafranil) vs. fluoxetine, fluvoxamine, 
paroxetine, sertraline, or citalopram; phenelzine (Nardil) vs. imipramine (Tofranil).  
Information from references 1 through 4 
 
 
There were no other consistent differences between classes of antidepressants. One trial reported 
less sexual dysfunction resulting from amitriptyline than from sertraline (NNH: seven), but 
numerous trials have not shown differences between clomipramine (Anafranil) and other 
SSRIs.
1,2
 One trial showed less sexual dysfunction resulting from fluvoxamine than from 
sertraline (NNH: six), but no differences between other SSRIs have been demonstrated.
1,2
 
Limitations to many of the published studies include small sample sizes, failure to control for 
baseline differences in sexual function between groups of patients, and lack of uniform means of 
inquiring into sexual adverse effects.  
Recommendations from Others  
Guidelines issued by the American Psychiatric Association
5
 (APA) and the American College of 
PhysiciansAmerican Society of Internal Medicine
6
 (ACPASIM) do not provide specific 
recommendations regarding which antidepressant to prescribe to minimize sexual dysfunction. 
[References 5 and 6--Evidence level 1A] The APA notes that SSRIs can carry a risk of sexual 
side effects, whereas the ACPASIM states that the data are insufficient to estimate incidence 
rates, thus making quantitative comparisons among antidepressants impossible.  
Clinical Commentary  
Bupropion appears to be the best antidepressant for use in patients who are concerned about 
drug-related sexual dysfunction. Amitriptyline may be a less expensive and suitable alternative, 
but it has other worrisome adverse effects. Nefazodone may have a low incidence of sexual 
dysfunction, but it has been associated with hepatotoxicity and was withdrawn from the 
Canadian and European markets. Moclobemide is not available in the United States.  
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